Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis

Javier Arranz-Trullén1,2†, Lu Lu1‡, David Pulido1†, Sanjib Bhakta2* and Ester Boix1*  
1 Faculty of Biosciences, Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona,  
Cerdanyola del Vallès, Spain, 2 Mycobacteria Research Laboratory, Department of Biological Sciences, Institute of Structural  
and Molecular Biology, Birkbeck University of London, London, United Kingdom

Tuberculosis (TB) continues to be a devastating infectious disease and remerges as a global health emergency due to an alarming rise of antimicrobial resistance to its treatment. Despite of the serious effort that has been applied to develop effective antitubercular chemotherapies, the potential of antimicrobial peptides (AMPs) remains underexploited. A large amount of literature is now accessible on the AMP mechanisms of action against a diversity of pathogens; nevertheless, research on their activity on mycobacteria is still scarce. In particular, there is an urgent need to integrate all available interdisciplinary strategies to eradicate extensively drug-resistant Mycobacterium tuberculosis strains. In this context, we should not underestimate our endogenous antimicrobial proteins and peptides as ancient players of the human host defense system. We are confident that novel antibiotics based on human AMPs displaying a rapid and multifaceted mechanism, with reduced toxicity, should significantly contribute to reverse the tide of antimycobacterial drug resistance. In this review, we have provided an up to date perspective of the current research on AMPs to be applied in the fight against TB. A better understanding on the mechanisms of action of human endogenous peptides should ensure the basis for the best guided design of novel antitubercular chemotherapeutics.

Keywords: antimicrobial peptides, innate immunity, tuberculosis, infectious diseases, mycobacteria, antimicrobial resistance, host defense

INTRODUCTION

Tuberculosis (TB) is currently one of the most devastating infectious diseases having caused around 1.8 million human deaths, with 10.4 million new cases reported in 2016 and approximately a third of the world's population harboring its persistent form of the disease-causing pathogen, Mycobacterium tuberculosis (Mtb) (1). Statistical analysis of epidemiological data have been shown a steady increase of the disease incidences over the past decade and new drug-resistant forms of TB cases are currently more than 5% of the total. TB has represented a major challenge worldwide and is the first/top leading cause of death from a single infectious microorganism (1).

Although the TB causing pathogen was first identified at the end of the nineteenth century, effective drugs against Mtb were only introduced during the second half of the twentieth century Xxs: streptomycin first, followed by isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB), and rifampicin (RIF). Unfortunately, the misuse and overuse of antibiotics for human welfare and farming industry have facilitated the emergence of resistant strains (2–4). Multidrug-resistant TB strains
contributions in the mammalian host innate defense (2). Accepted that AMPs are multifunctional molecules with key functions in their attempt to reach the market, nowadays, it is widely acknowledged that antimicrobial peptides (AMPs) and the difficulties encountered in their attempt to reach the market, nowadays, it is widely accepted that AMPs are multifunctional molecules with key functions in their attempt to reach the market, nowadays, it is widely accepted that AMPs are multifunctional molecules with key contributions in the mammalian host innate defense (2, 3, 16, 17). In addition, due to the evolution of drug resistance among Mtb strains and their rapid spread across the globe, the use of both natural and synthetic AMPs and their combination with conventional drugs (18, 19) is enabling the creation of a new generation of truly promising antibiotics (20–23). As Mtb can survive and replicate within macrophages, novel anti-TB agents should be able to target the intracellularly dwelling mycobacteria without causing any damage to the host. In this review, we will focus on AMPs, either exploited naturally by our immune system or artificially synthesized, as potential therapeutics to overcome and eradicate the pathogen infection. Special attention will be paid to the diverse mechanisms that can mediate the AMPs’ action against TB infection. Finally, we will discuss the advantages, limitations, and challenges of AMPs for its merchandising and clinical use.

THE POTENTIAL OF ANTIMICROBIAL PEPTIDES IN THE ANTI-TB CHEMOTHERAPY: UNRAVELING THEIR MECHANISMS OF ACTION

Emergence of extensively antimicrobial resistance toward current anti-TB drugs has drawn back our attention toward alternative once neglected therapeutic strategies, including a resurgence in AMPs research (2, 30). Expression of endogenous AMPs represents one of the most ancient host defense strategy of living organisms. Their multifunctional mode of action, natural origin, and effectiveness at low concentration have positioned them as prospective candidates in future antitubercular therapeutics market (3, 7, 31, 32). Notwithstanding, to ensure a successful therapy prior to drug design, we must deepen in the knowledge of the underlying mechanism of action of our own innate immunity players.

Despite a low level of amino acid sequence identity, AMPs adopt similar structural folds, indicating the existence of parallel mechanisms of antimicrobial action among distant living organisms (33). Among a significant variety of AMPs traits, we can outline the main common properties. We will review here the main known human AMPs secreted by innate immunity cells to counterbalance mycobacterial infections along with their mode of action.

A UNIQUE AND PATHOGENIC BACTERIA

Although most mycobacteria (more than 150 species reported to date) are environmental, only a few species can infect both humans and livestock alike. Mtb is an obligate human pathogen with a low mutation rate (24) and no horizontal gene transfer (25). The TB-causing bacilli have coevolved with our civilization over millennia and its indefinite latency periods probably evolved as an adaptation to the sparse geographic distribution of early human settlements. However, our modern one-world globalization might be triggering a worryingly shorter latency in TB (4).

Tuberculosis is mainly an airborne respiratory disease that is conveyed through aerosolized particles. Once in contact with the lung tissues, Mtb can enter and dwell within the host macrophages and other phagocytic immune cells. Immediately after, the infection triggers a complex immune response, and as a result, the pathogens may manage to establish a long-term residence within the host (4, 12, 26). During the primary infection phase, the host defense response sequesters the bacilli in confined cages at the lung alveoli, known as granuloma (Figure 1). During this early period the infected alveolar macrophages, the favorite mycobacterial lodge, are actively releasing pro-inflammatory effectors and other signaling molecules to remove the resident pathogens (8, 27). Following, the tubercle bacilli manage to downregulate the host cell expression profile and enter into a dormant state (26, 28). Ultimately, granuloma will mature and endure a necrosis process. Dormancy responses will facilitate the pathogen’s long-term intra-host survival, and enable it to withstand the necrotic granuloma environment. Upon reactivation of dormant cells, the bacilli will start growing extracellularly and cover the lung cavities with a biofilm layer enriched with the most drug-resistant cells (29). The spread of reactivation is then mediated by coughing induced granuloma mechanical shear (12, 28).

Mycobacterial Cell-Wall: A Complex Barrier Particularly Difficult to Overcome

The unusual high antimicrobial resistance in mycobacteria is primarily due to the unique complexity of its cell wall. The complex network of macromolecules such as peptidoglycan, arabinogalactan, and mycolic acids (MAgP complex), which are conglomerated by other proteins and polysaccharides, confirm the main
The unique covalently-linked MAgP complex of Mtb is a result of mycobacterial adaptation to secure the intracellular survival against continuous selective pressures exerted by the host immune system and other hostile environments. Furthermore, it has been found that the characteristics and composition of the cell wall can be modified during infection (38). The length and structure of the mycolic acids have been related to bacterial intracellular survival and are one of the favorite targets of successful antibiotics (12, 37) (Figure 1). The first step of AMPs interaction with the pathogen is generally mediated by their positive net charge and hydrophobicity. Unlike eukaryotic cells, in which the anionic lipids are predominantly in the inner leaflet of the lipid membrane providing a neutral cell surface, prokaryotic cells expose a negatively charged surface. Many AMPs can exert a direct killing mechanism against mycobacteria through cell membrane disruption. The binding between the mycobacterial anionic surface compounds and mycobacterial cell-wall scaffold and constitute a highly difficult crossing-barrier for antimicrobial agents (34–37) (Figure 1). The emergence of Mtb strains with acquired resistance to INH and EMB drugs that target the mycolic acids synthesis, demands novel strategies. The binding between the mycobacterial anionic surface compounds and the drug targets the cell-envelope integrity (2). In this context, dermcidin, a human peptide secreted by sweat glands (39) has been predicted to inhibit the mycolyl transferase enzyme efficiently (40). Other re-emerged research lines target the cell-wall peptidoglycan metabolism (12). On the other hand, one of the main mechanisms by which the AMPs exert their effect is based on the ability to disrupt or permeate the cell membrane (Figure 1), either fully disrupting the lipid bilayer or by creating transient pores (41). Numerous AMPs have acquired amphipathic and cationic structures as short β-sheets and α-helices that allow them to establish interactions with bacterial membranes (42).
the cationic residues of the peptides promotes the membrane permeabilization (43). Contribution of the peptide cationicity has been corroborated in distinct AMPs by amino acid substitution. As an example, the replacement of lysines by arginines in lactoferrin (LF) variants enhanced their mycobactericidal effect (44). In addition, although the highly hydrophobic scaffold of the mycobacterial envelope offers resistance to AMPs action, the increase in the proportion of α-helical structure and peptide hydrophobicity has been engineered as an alternative strategy to enhance their mycobactericidal features (48). Moreover, some AMPs are directly targeting surface cell-wall proteins to interfere in the cell ion exchange and inhibit the mycobacterial growth. AMPs can interact with the mycobacterial membrane proteins such as ATPases and inhibit the cell pH homeostasis (45, 46). Interestingly, AMPs inducing the membrane permeation can be applied as adjuvants to conventional antibiotics (47).

**Intracellular Targets**

Although most of the known AMPs exert their action at the bacterial membrane level, there is a growing number of identified peptides endowed with other previously overlooked targets. Many AMPs have the ability to translocate across the membrane and novel methodologies are bringing the opportunity to identify the peptide interactions with intracellular components (48). As an example, human neutrophil peptides can effectively cross the lipid bilayer without causing significant membrane damage and bind to nucleic acids (49, 50). Selective mycobactericidal action has been achieved by synthetic antimicrobial peptides (SAMPs) that can be internalized by mycobacterial cells and bind to DNA, inhibiting replication, and transcription processes (51). Interestingly, the intracellular action can be achieved at very low peptide concentrations, reducing the potential toxicity to host cells.

**Phagosome-Lysosomal Pathway and Autophagy Modulation**

*Mycobacterium tuberculosis* has evolved to dwell within one of the most inhospitable cell types, the macrophage. The tubercle bacillus is able to interfere with the phagosome maturation pathway, blocking the transfer of the phagocytosed compounds to lysosomes (52). At this stage, several mechanisms take place toward the elimination of the pathogen, among them: production of reactive oxygen and nitrogen species, vacuole acidification, lytic enzymes activation, and changes in ion fluxes (53). *Mycobacterium* is able to interfere not only in the recruitment of vesicular ATPase proton pump but also in the acquisition of markers for the endocytic pathway. The TB causing bacilli promote the fusion with early endosomal vesicles but arrest the fusion to the lysosomal compartment, thereby protecting its phagosomal niche from acidification and avoiding the action of lytic enzymes. Moreover, the pathogen inhibits the phosphatidylinositol kinase, reducing the phosphatidyl inositol triphosphate (PIP3) levels and impairing the phagosome maturation (54). The modulation of the phagocytic maturation seems to be carried out by components of the mycobacterial cell wall, such as the mannosylated liparabinomannan (7, 54). Altogether, mycobacteria ensure their survival within the host cell by intercepting the autophagic machinery at distinct levels (Figure 2) (8, 55). On their side, many AMPs promoting the phagolysosome formation also contribute to remove the pathogen intruder (56). Thereby, one of the strategy undertaken by the mycobacteria is the downregulation of AMP expression within the macrophage (57). Autophagy has other beneficial effects for the host, such as the restriction of inflammation (58). Indeed, one of main currently used anti-TB drug is rapamycin, an autophagy activator, and the search of novel autophagy inducers is a priority (3, 23, 59).

**Immunomodulatory Activities**

Undoubtedly, immunotherapy is at the frontline of TB eradication programs. Following the bacteria engulfment by alveolar macrophages, the mycobacterial components are identified by several pattern recognition receptors resulting in the activation of signaling pathways and the subsequent leukocyte activation (27, 58). In this scenario, participation of endogenous AMPs during the host immune response (Figure 2) is key for a successful eradication of infection (28, 60). We can differentiate two main phases that would mediate the infection process, in the early acute step the AMPs can directly kill the MtB bacilli, whereas in the secondary late step, the AMPs immunomodulatory action takes the leadership (26). Pro and anti-inflammatory effects can be induced by AMPs mediated by the release of a variety of cytokines (16, 23, 57). Interestingly, the same AMP can have a pro-inflammatory action at an early infection stage, while shifting to anti-inflammatory activity during late infection (3). Indeed, many immune factors play an essential role in the mediation of the infective process (8). For instance, the production of cytokines, which are important for the immune response, such as interferon gamma (IFNγ), are undermined by the mycobacterial infection (61).

**HUMAN ENDOGENOUS AMPs INVOLVED IN THE FIGHT AGAINST TB INFECTION**

Following mycobacterial infection, a large assortment of antimicrobial peptides is released by our innate immune cells into the affected tissue (62). AMPs as key players of the non-specific immune response (2, 17) have attracted renewed attention as novel therapeutics and several comprehensive databases are now available open to the scientific community (2, 63–65). We describe, here, the main natural human AMPs involved in the fight against TB infection (Table 1).

**Cathelicidins**

Cathelicidins constitute a mammalian family of antimicrobial peptides mostly expressed in leukocytes and epithelial cells in response to different pathogens, contributing to their eradication (7, 37, 72). The human cationic antimicrobial peptide-18 (hCAP-18) is the unique known human member and the leading AMP in TB therapeutics (7, 131). hCAP-18 is essentially conformed by two regions, a highly conserved N-terminal sequence, called cathelin and the bactericidal C-terminal region known as LL-37, released by proteolysis (132, 133). LL-37 contributes to the recruitment of T-cells to the site of infection (66) and displays the activity to block mycobacterial growth (5). Cathelicidins interact with the mycobacterial membrane, releasing the AMPs action, thereby protecting the intracellular components (47). Cathelicidins contribute to the modulation of the host immune response, blocking the transfer of the phagocytosed compounds and promoting the phagolysosome formation also contribute to remove the pathogen intruder (56). Thereby, one of the strategy undertaken by the mycobacteria is the downregulation of AMP expression within the macrophage (57). Autophagy has other beneficial effects for the host, such as the restriction of inflammation (58). Indeed, one of main currently used anti-TB drug is rapamycin, an autophagy activator, and the search of novel autophagy inducers is a priority (3, 23, 59).
diverse immunomodulatory and antimicrobial activities (57, 73), undertaking a prominent role during mycobacterial infection (57, 69). In particular, a significant overexpression of LL-37 on neutrophils, epithelial cells, and alveolar macrophages has been observed during Mtb infection (67). The infection of mononuclear cells promotes the upregulation synthesis of LL-37 via the vitamin D induction pathway (134). Interestingly, vitamin D deficiency correlates with susceptibility to tuberculosis, while supplementation with vitamin D derivatives improves the efficiency to overcome TB (75). Phagosomal pathway is known to be a key defensive procedure to eradicate Mtb and recent studies point to vitamin D3 as an inducer of autophagy in human monocytes as well as an inhibitor of intracellular mycobacterial growth, via upregulation of autophagy-related gene expression (3, 76, 134). The LL-37 peptide thereby decreases, directly or indirectly, the rate of intracellular bacteria proliferation. Recently, transcriptome profiling confirmed the direct contribution of LL-37 at the lysosomal compartment (135). Jointly, all these experimental evidences highlight cathelicidin LL-37 not only as a forthright antimicrobial peptide but also as a prominent modulator of autophagy during mycobacterial infection (3, 77).

Defensins

Defensins were the first AMPs related to TB by pioneer researchers (49, 50, 81, 136). Defensins are a set of cationic and cysteine-rich peptides with immunomodulatory and microbicidal properties that constitute one of the major and most diverse group of AMPs in the mammalian pulmonary host defense system (3, 16, 137). They are classified according to their structure into alpha, beta, and theta. They show substantial variation in terms of amino acid sequences, and show a diversity of mechanism of action at membrane and intracellular levels. In addition, defensins can be induced and activated by proteolysis pathways to acquire their antibacterial activity (138). Interestingly, high-throughput gene
expression of peripheral blood mononuclear cells profile analysis from patients with tuberculosis and Mtb-infected healthy donors revealed the existence of an overexpression of defensins levels in TB patients (139). The peptides were observed to bind to Mtb cells within the macrophage phagosome (140). The essential participation of defensins in the host fight against TB infection has also been corroborated in a murine model (23, 85).

Within the defensin family, we find a variety of cellular source types (Table 1) (82). Noteworthy, the β-defensin2 (HBD2) and the α-defensin (HAD) expression are inducible by mycobacteria wall components in epithelial cells and eosinophils, respectively (79, 81), and could have a preservative role in vivo against TB infection. Upregulation of HDB3 and 4 were also reported effective in Mtb MDR-infected mice (83).

### Human Neutrophil Peptides (HNPs)

Human neutrophil peptides are α-defensin type AMPs mainly secreted by neutrophils (50), although low levels of expression...
have also been detected in monocytes, eosinophils, and epithelial cells (79). HNP-1-4 expression is induced by TB infection (7, 37, 82). On the other hand, although macrophages express only small amounts of HNPs, high intracellular levels can be reached via neutrophil-phagocytosis. Interestingly, HNPs have been observed to colocalize with tuberculosis bacilli in early endosomes (84). Moreover, the administration of HNPs maximizes the antimicrobial capacity of macrophages against Mtb (50) and HNP1 was proven effective in a Mtb-infected mouse model (50). HNP-1 can permeabilize the Mtb cell membrane by forming transmembrane pore and then bind to intracellular DNA (7, 50). Interaction with nucleic acids could subsequently inhibit the main cell functions, as transcription and translation (48). On the other hand, combination studies using HNPs and β-defensins with conventional antibacterial drugs have shown a synergistic effect. Therefore, the AMP adjuvant role can reduce the required drug dose and also significantly diminish the bacterial load in vital organs (141). Overall, these findings together with recent experimental work with tuberculosis animal models entrench the therapeutic application in favor of the whole defensin family (7, 37, 83).

**Hepcidin**

Hepcidin (Hepc) is a short and highly cationic antimicrobial peptide that was originally detected in serum and urine (142). It adopts a hairpin loop that encompasses two short beta-strands. Hepcidin is predominantly synthesized in hepatocytes and is released from a precursor by proteolysis. Its expression is induced by infectious or inflammatory processes and plays a prominent role in the iron homeostasis, regulating uptake, and mobilization (92, 143). Specifically, hepcidin can downregulate the transmembrane transport of iron through its union with ferroportin, a transmembrane protein that exports iron to the extracellular space (93). The reduction in extracellular iron concentrations makes pathogen invasion conditions more hostile (91). Interestingly, during infection, hepcidin is released into the bloodstream and is considered to be responsible of the anemia associated with inflammation (94). Indeed, anemia is a common difficulty encountered in TB (144). Moreover, Lafuse and coworkers demonstrated that mycobacterial infection induced the emergence of high levels of hepcidin in macrophages phagosomes and confirmed the peptide inhibition of Mtb growth in vitro (87). Further research also reported the presence of hepcidin in other innate cell types such as dendritic cells. The peptide expression in non-phagocyte cells suggests an extracellular mycobactericidal activity mediated by iron reduction in both alveolar and interstitial spaces (88). Particularly, due to the hepcidin effect on iron levels, differences in the expression of the peptide could be related to different phenotypes of iron homeostasis in TB patients. A significant correlation was observed between serum hepcidin levels and the promoter polymorphism in TB patients and was suggested to be considered in the diagnosis and prognosis of tuberculosis (145).

**Lactoferrin**

Lactoferrin is another AMP related to iron homeostasis regulation. It is a multifunctional iron binding glycoprotein present in several tissues and most human body fluids. It has a molecular weight of 80 kDa and belongs to the transferrin family (99). LF and its natural N-terminal fragment released by proteolytic cleavage (Lactoferricin, LFcin) participate in host defense and have wide spectra antimicrobial effects (37, 44, 98). Noteworthy, LF is the only AMP given by systemic administration that is currently in clinical trials (146). Diverse studies have demonstrated the presence of LF in macrophages and blood cells and its activity against *Mycobacterium*. Moreover, LF immunomodulatory capacity can also contribute to the eradication of TB. Particularly, it has been observed that mice treated with LF manifest an increase in the proportion of IL-12/IL-10, which results in increased Th1 cells, with a protective role against Mtb (100, 101). The anti-inflammatory properties of human and mouse LF were also corroborated in another Mtb mouse infected model (102). In addition, other studies clearly demonstrated the immunomodulatory role of LF, improving BCG-vaccine efficacy when used as adjuvant (147, 148). Recently, it has been reported that LF expressed in azurophilic granules of neutrophils is capable of killing *M. smegmatis* (104).

**Lipocalins**

Lipocalins are a family of peptides involved in cellular traffic and inflammation which are also related to the iron homeostasis (149). Lipocalin2, also called neutrophil gelatinase associated lipocalin, is expressed in neutrophils and displays anti-TB activity (130).

**Azurocidin**

Azurocidin, a leukocyte polymorphonuclear (PMN) granule protein, is a cationic antimicrobial protein of 37 kDa, also called CAP37 or heparin-binding protein, due to its high affinity for heparin (103). Shortly after its discovery it was found that azurocidin, like other antimicrobial proteins, not only displayed an antimicrobial activity but was also capable of exerting a mediating role in the modulation of the host defense system (150). Azurocidin is stored in secretory granules and is released into the endothelial area by PMN cells, rapidly reaching the infected or inflammation area (151). Azurocidin, at the front line of infection, activates monocytes, macrophages, and epithelial cells (152). Moreover, azurocidin has a wide range antimicrobial activity, working efficiently at acidic pH, a condition promoted in mature phagolysosomes (153). Interestingly, it has recently been reported that azurophilic granule proteins are implicated in mycobacterial killing, facilitating the fusion of mycobacteria-containing phagosomes with lysosomes (104).

**Elastases**

Elastases are serine proteases secreted by neutrophils and macrophages involved in the fight against pulmonary infections (107). One of the best studied elastase is the neutrophil elastase (NE), also known as elastase2, a 29-kDa protein expressed during myeloid development and secreted by neutrophils during episodes of infection and inflammation (107, 108). NE was reported to confer a protective effect against *M. bovis* in mice pulmonary tract (109). Many studies emphasize NE multi-functionality; the protein can break the tight junctions to facilitate the migration of PMN cells to the inflammation/infection area and induce cell chemotaxis (108). The neutrophil granule protein can work...
within the macrophage phagosomes (154). Complementarily, NE is also reported to kill mycobacteria extracellularly in a rather peculiar way. Neutrophil granules can release their protein cargo together with chromatin, resulting in the formation of extracellular fibrillar structures that facilitate bacteria arrest. NE colocalizes with the neutrophil extracellular traps and can facilitate the degradation of virulence factors (110, 155). Interestingly, heavily infected macrophages can also explode and form extracellular traps, a process which is also regulated by elastases (106, 111).

Cathepsin (CTS)
Cathepsin is another serine protease involved in the host defense against TB infection that is mainly expressed in neutrophils and macrophages (130, 156). Procathepsins are converted to the mature enzyme in acidic conditions and are active within the lysosomal compartment (30). The Mtb bacilli can downregulate CTSs expression in macrophages to ensure its intracellular survival (120, 156). The antimicrobial protease is proposed to protect the host mostly by an immunoregulatory role rather than a direct bacteria killing activity, as observed in an infection mouse model (122). Recent work using the zebrafish/M. marinum model indicates the involvement of macrophage lysosomal CTSs to control the TB infection at the granuloma level (121, 157).

Granulysin (GNLY)
Granulysin is a small cationic human antimicrobial protein expressed by lymphocytes that is upregulated by HIV/TB coinfection (37, 158). GNLY can enter the macrophages and is able to disrupt the bacillus envelope (7).

Calgranulin
Calgranulin, also called calprotectin, is another AMP that is used as a TB infection marker in blood samples (30, 124, 127). Calgranulin is a calcium-binding protein that also interacts avidly with Zn\(^{2+}\) cations. Binding to Zn\(^{2+}\) activates the peptide antimicrobial activity. Recently, calgranulin overexpression has been associated to anti-TB activity at the macrophage intracellular level by promotion of the phagolysosomal fusion (30, 126).

Ubiquitin-Derived Peptides
Ubiquitin-derived peptides are ubiquitinated proteolytic peptides which can also be classified as AMPs (7, 37, 159). In particular, ubiquitin-conjugated peptides as products of the proteasome degradation activity accumulate in the lysosome and can inhibit Mtb growth within the autophagolysosome (129). Ubiquitin by itself is innocuous while ubiquitinated peptides, such as Ub2, can permeate the mycobacteria membrane (160).

Human Antimicrobial RNases
Human antimicrobial RNases are small secretory proteins (~15 kDa) belonging to the RNaseA superfamily. They are highly cationic and possess a wide range of biological properties, representing an excellent example of multitasking proteins (112, 161). The family comprises eight human members, expressed in diverse epithelial and blood cell types.

RNase3, also known as the eosinophil cationic protein (ECP), is mainly expressed during infection and inflammation in the secondary granules of eosinophils (162) and secondarily in neutrophils (163). Complementarily, the signal peptide of the ECP (ECPsp) was found to promote the migration of macrophages via pro-inflammatory molecules to sites of infection and inflammation (164). Interestingly, ECP is secreted, together with \(\alpha\)-defensin, in response to M. bovis BCG infection (79). Although the recruitment of eosinophils in the respiratory tract during Mtb infection was first regarded as a mere response to inflammation (165), further work has shown that this cell type together with neutrophils can directly participate in the removal of the infection focus (166). Eosinophils are activated via TLR2 induction by the specific mycobacterial wall component, the lipomannan (79). Eosinophils, together with neutrophils, would then release the content of their granules into the granuloma macrophages (84, 159). To note, the eosinophil peroxidase, another eosinophil protein stored in the secondary granules, is also endowed with antimycobacterial activity (119). On the other hand, macrophages express upon bacterial infection two additional RNases, RNase6 and RNase7 (114). In addition, human RNase7, also called the skin derived RNase, is also secreted by keratinocytes and exerts a protective role against a variety of pathogens at the skin barrier (39, 115). Interestingly, RNase7, together with RNase3, can eradicate mycobacteria in vitro (117). Moreover, very recent results indicate that human RNases 3, 6, and 7 can also inhibit the growth of mycobacteria in a macrophage infection model (167). Considering that RNase6 and RNase 7 expression is induced in macrophages upon bacterial infection (114), one might hypothesize that these antimicrobial proteins can also play a physiological role against intracellular dwelling mycobacteria. Eventually, we cannot disregard a complementary contribution of the RNases reported immunomodulatory properties, such as the induction of pro-inflammatory cytokines and the dendritic cell chemotraction (168, 169).

SYNTHETIC ANTIMICROBIAL PEPTIDES
In the race against TB, novel synthetic AMPs with potent mycobactericidal activities have been developed (2, 19, 22, 37, 170). AMP synthetic analogs are often considered to be the next generation of antibiotics and have attracted the attention of many companies aiming to develop new anti-TB therapies against drug-resistant strains (35). Following, we summarize the main SAMPs successfully designed (Table 2).

One of the favorite applied strategies for the design of potent AMPs is the engineering of stabilized amphipathic \(\alpha\)-helix that are enriched with selected antimicrobial prone amino acids. Complementarily, peptide modifications are devised to endow them with enhanced resistance to proteolysis; thereby improving their in vivo stability and efficacy. The \(\alpha\)-LAK peptides are a family of synthetic peptides consisting of 25 \(\alpha\)-enantioomer amino acid residues in a primary sequence designed to adopt a left-handed \(\alpha\)-helix conformation and containing eight lysine residues (175). The peptides were designed to enhance their antimicrobial activity and decrease their hemolytic effect (188), providing efficient antimycobacterial activity at non-toxic concentrations. Furthermore, \(\alpha\)-LAK peptides can be administered as inhalable dry powder (176). Another synthetic \(\alpha\)-helical peptide, the
### TABLE 2 | Synthetic peptides effective against mycobacteria.

| Peptide         | Modifications                           | Source                                | Mechanism/antimicrobial activity                                                                 | Reference |
|-----------------|-----------------------------------------|---------------------------------------|---------------------------------------------------------------------------------------------------|-----------|
| 1-C13mer        | Tetrameric form; oligo-N-substituted glycines (peptide) and alkylation | Design de novo                        | Pore formation                                                                                   | (171)     |
| A18G5, A24C1ac, A29C5FA, and A38A1guan | Derived from the insect proline-rich peptide Apidaecin | Hoffmann R, Czihal P Patent WO2009013262 A1. 2009 (172) | Bacterial membrane permeation/inhibition of protein synthesis                                    |           |
| CAMP/PL-D       | Short cationic peptides (10 AA) rich in W and R selected from peptide libraries | Derived from cecropin A: mellitin     | Bacterial cell wall disruption                                                                     | (174)     |
| E2 and E6       | Derived from bacteriin (bovine cathelicidin) Bac8c (8 AA) | Derived from bacteriin                | Bacterial cell wall disruption                                                                     | (174, 177)|
| HHC-10          | Derived from bacteriin                   | Derived from bacteriin                | Bacteria membrane lysis                                                                         | (178*), (179)|
| hLFcin1-11/ hLFcin17-30 | Derived from lactoferrin (All-R and All-K substitutions) | Derived from lactoferrin              | Bacterial cell wall and membrane lysis                                                           | (44)      |
| LLAP            | Derived from LL-37                       | Inhibition of ATPase                  | MIC (M. smegmatis mc²155): 600 µg/mL                                                            | (183)     |
| LLKK18          | Hyaluronic acid nanogel conjugation       | Hyaluronic acid nanogel conjugation   | Pore formation/Immunomodulatory activity                                                         | (184)*    |
| MJ1140          | Derived from Streptococcus mutans lantibiotics | MJ1140                                | Inhibition of cell wall synthesis/On preclinical stage. Effective on active and dormant Mtb MDR | Oragenics Inc Patent WO2013130349A (185)*         |
| MiAP            | Derived from Magainin-I                  | Inhibition of ATPase                  | MIC (H37Ra): 300 µg/mL                                                                          | (46)      |
| Pin2 variants   | Derived from pandinin2 (short helical peptides) | Membrane disruption                  | Mtbs H37/Rv and Mtbs MDR: 6–14 µg/mL                                                            | (186)     |
| RN3(1-45)       | Derived from human RNases N-terminus     | Bacterial cell wall disruption        | MIC (M. vaccae; M. aurum; M. smegmatis mc²155; M bovis BCG in vitro: 10–20 µM and ex vivo (M. aurum); 5–10 µM | (117, 167)|
| Synthetic AMPs (SAMPs-Dma) | Dimethylamination and imidazolization | Design de novo                        | Cell penetration and DNA binding/ Synthetic antimicrobial peptide-Dma10: MIC (M. smegmatis mc²155): <20 µM | (51)      |
| X(LLKK)2X: II-D, II-Om, II-Dap, and IIDap | Peptide d-enantiomer, ornithination, 2,4-diaminobutyric acidification, and 2,3-diaminopropionic acidification | Pore formation                         | M(L LLKK)2M: MIC (Mtbs H37/Rv): 125 µg/mL; X(LLKK)2T: effective against MDR-TB                   | (22, 187)|

*Reported activities tested in vivo using murine infection models.
M(LLLK)2M, was proven successful against MDR strains when combined with RIF (187). On the other hand, a short synthetic cathelicidin variant (the HHC-10) is able to inhibit the growth of M. bovis BCG both in vitro and in a mouse model (178).

Interestingly, the N-terminus derived peptides of human antimicrobial RNases can reproduce the parental protein activity against several tested Mycobacterium species (117, 167). The RN(1-45) peptides encompass a highly cationic and amphipathic region that adopts an extended α-helix in a membrane-like environment (189). In addition, the RN3(1-45) and RN6(1-45) peptides include an aggregation prone sequence which promotes bacterial cell agglutination (117, 167, 190), a property that can facilitate the microbial clearance at the infectious focus (190).

Recently, particular interest has been drawn by a collection of short synthetic peptides with immunomodulatory activities, the innate defense regulators (IDRs). The peptides are effective at very low concentration and thereby can elude any toxicity to the host (181). They do not display a direct bactericidal activity but can promote the proper endogenous expression of antimicrobial agents by the host cells. Among others, the peptides enhance the release of chemokines and downregulate the inflammation pathway (181, 182). The IDR peptides, such as the IDR-1018 (Table 2), have been tested successfully in a MDR-TB infected mouse model by intra-tracheal administration (180). Likely, immunoregulatory peptides will take a leading role in the treatment of immunocompromised patients in a near future (16).

**AMPS TO COMBAT ANTIMICROBIAL RESISTANCE IN TB: A TIME FOR HOPE**

In recent years, thousands of antimicrobial peptides have been identified from natural sources, mostly classified as key players of the non-specific host defense response (30, 33, 191). On the other hand, despite the existence of a wide range of successful antibiotics since their entry into the worldwide trade, nowadays there is an increasing demand of novel drugs to tackle multidrug-resistance mycobacteria strains (2, 20, 192). The antimicrobial proteins and peptides (AMPs), given their direct bacilli killing mechanism and immunomodulatory properties provide an attractive pharmacological potential against mycobacterial infections (see Table 3 for a summary of main AMP-based therapies). However, despite their appealing properties, AMPs are still facing major challenges to join the pharmaceutical industry (30–32). The main advantages and disadvantages associated with AMPs are listed in Table 4. Although the high cost of synthesis is one of the main drawbacks that the manufacturing of peptides faces, some companies are already managing commercial-scale peptide production platforms. For example, recombinant AMPs can be prepared in fungi and plants at high yield and low cost (2). Another drawback of AMPs therapy is their susceptibility to proteolytic cleavage, in particular when delivered by systemic administration (2, 31). In addition, the antimicrobial activity of some peptides appears to be decimated in physiological saline and serum conditions (32, 193). Novel design strategies are focusing on the production of cheaper and reduced-size analogs (2, 194) with improved selectivity toward prokaryotic targets and broaden therapeutic indexes (195). To improve the peptide bioavailability and stability in vivo several strategies have been developed such as incorporation of non-natural amino acids, backbone mimetics, conjugation with fatty acids, N and C- terminus modifications (196). The peptide performance can also be improved by intra-tracheal administration (184). In addition, encapsulation within biodegradable particles or liposomes improves the distribution of the drug toward the site of action (31, 196). Fortunately, macrophage nature by itself should promote the engulfment of such nanovehicles (19) and extensive research has been applied to define the parameters that determine the nanoparticles uptake by the phagocytic cells and intracellular traffic (2, 197). Very recently, a novel delivery system has been achieved by a LL-37 analog embedded within a hyaluronic nanogel. The self-assembled polymer stabilizes the peptide inside its hydrophobic core, allows a higher dose cargo and promotes the macrophage uptake, with increased

---

**TABLE 3 | AMPs based strategies to develop novel anti-TB drugs.**

| Strategy | Example |
|----------|---------|
| Pro-autophagy AMPs | Cathelicidins (56, 58, 78); azurocidin (104); calgranulin (126) |
| Anti-inflammatory AMPs | Defensins (23, 82); AMP binders to antigenic molecules (23); LL-37 inhibition of TNF-α and other pro-inflammatory cytokines (57); synthetic innate defense regulator (IDR) peptides (181); synthetic LLKKK18 (LL-37 analog) (184); lactoferrin (100) |
| Pro-inflammatory AMPs | LL-37 (57, 74); defensins (82); hepcidin (84) |
| Chemotaxis induction by AMPs | Defensins (23); IDR synthetic peptides (23); LL-37 (2, 58, 181); elastases (108) |
| AMP synergy | with current antibiotics: HNP1 + isoniazid/ rifampicin (141); HBD1 + isoniazid (217); synthetic α-helix AMP + rifampicin (18) |
| | with immunomodulators: HNP1 and HBD2 + L-isoleucine (206) |
| | with nanoparticles (19) |
| Induction of host AMP expression | Search for novel LL-37 inducers (218); vt D3 and phenylbutirate (PBA) for LL-37 (16, 28, 77, 204); L-isoleucine for β-defensins (83); aroylated phenylendiamine inducers (203) |
| AMP-based gene therapy | Adenovirus encoding LL-37 or HBD3 (219) |
| AMP nanodelivery | Nanovehicle systems: nanoparticle size, surface chemistry, and mechanical properties to enhance macrophage uptake (2); liposomes (2, 196); nanogels (184, 196); aerosolization (176, 196) |

*Representative examples are provided for each indicated strategy.*
This new affront (AMPs might develop novel resistance strategies to face back either externally administered or endogenous overexpressed to an overdose of AMPs. Mycobacteria pathogens exposed to unpredictable long-term consequences of exposing the bacteria to the induction of the immune response in immunocompromised patients. Synergy with current antibiotics. Potential use as antibiotic adjuvants.

### Application strategy

| Exogenous AMP administration | Broad-spectrum activity | Rapid direct killing mechanism | High affinity toward mycobacterial surface | Enhanced uptake by macrophages | Very low/no toxicity of natural human AMP | Rapid clearance in host tissues | Beneficial effects to the host (anti-inflammatory, pro-autophagy, anti-tumoral, etc.) | Low rate of bacterial resistance emergence | High stability and efficacy of modified peptide derivatives | Reduced manufacturing cost by new recombinant methodologies | Gene therapy can restore endogenous AMPs levels in immunocompromised patients | Synergy with current antibiotics | Potential use as antibiotic adjuvants |
|----------------------------|-------------------------|-------------------------------|------------------------------------------|--------------------------------|----------------------------------------|-----------------------------|---------------------------------------------------------------------------------|----------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Endogenous AMP induction   | Efficient at very low concentrations | Reinforcement of the immune response in immunocompromised patients | Prevention of latent mycobacterial reactivation |

### Disadvantages

| Rapid degradation following oral/systemic administration | Low stability in human biological fluids | Potential undesirable side-effects at high concentration (tumorigenesis, angiogenesis, etc) | Potential toxicity via oral/systemic administration | High cost of chemical synthesis |

### CONCLUDING REMARKS

Peptide-based therapy to treat infectious diseases is recently experiencing resurgence. AMPs, as mere components of the immune system, promote the direct killing of mycobacteria and often have immunomodulatory effects. Their non-specific pleiotropic mechanisms of action and unique immunomodulatory properties over conventional antibiotics have awakened the pharmaceutical market interest. Moreover, the efficacy of BCG vaccine is highly variable and the alarming increase of extensively drug-resistant strains of Mtb is a major global health emergency to address. In this context and considering the limitations in the current antituberculosis drug treatment, AMPs represent an immediate alternative approach in tackling antimicrobial resistance. Scientific evidences provide a solid basis to ensure that the future development of peptide-based therapy will continue to address the unsolved drawbacks that the pharmaceutical industry is currently facing. Novel research methodologies and integrated interdisciplinary strategies should provide the opportunity to boost current antimicrobial peptide research efforts in the fight against tuberculosis.

### AUTHOR CONTRIBUTIONS

JA-T, LL, DP, SB, and EB contributed to the original draft and edited versions. JA-T and LL prepared the graphical material and JA-T, DP, LL, and EB prepared the tables. SB and EB wrote, edited, and revised the final manuscript version. All authors approved the final manuscript version.

### FUNDING

Research work was supported by the Ministerio de Economía y Competitividad (SAF2015-66007P) co-financed by FEDER funds. LL is a recipient of a CSC predoctoral fellowship. JA-T was a recipient of a predoctoral fellowship (PIF, UAB). SB is a Cipla distinguished Fellow in Pharmaceutical Sciences.
REFERENCES

1. WHO. Global tuberculosis report 2016. World Heal Organ Glob Tuberc Rep. Geneva (2016).
2. Silva JP, Appelberg R, Gama FM. Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv (2016) 34:924–40. doi:10.1016/j.биотехадв.2016.05.007
3. Rodríguez Plaza JG. Prospective tuberculostatic treatment: peptides, immunity and autoaphagy. J Mol Genet Med (2014) 8:128. doi:10.4172/1747-0862.1000128
4. Eldholm V, Balloux F. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol (2016) 24:637–48. doi:10.1016/j.tim.2016.03.007
5. Zager EM, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis (2008) 8:10. doi:10.1186/1471-2334-8-10
6. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol (2009) 7:81–7. doi:10.1038/nrnmicro2048
7. Khusro A, Aarti C, Agastian P. Anti-tubercular peptides: a quest of future therapeutic weapon to combat tuberculosis. Asian Pac J Trop Med (2016) 9:1023–34. doi:10.1016/j.апджтм.2016.09.005
8. Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology (2012) 217:363–74. doi:10.1007/j.2012.07.008
9. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 345:1098–104. doi:10.1056/NEJMoa0111110
10. Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents. Pediatr Rheumatol Online J (2014) 12:45. doi:10.1186/1546-0096-12-45
11. Montoya-Rosales A, Castro-Garcia P, Torres-Juarez F, Enciso-Moreno JA, Rivas-Santiago B. Glucose levels affect LLI expression in monocyte-derived macrophages altering the Mycobacterium tuberculosis intracellular growth control. Microb Pathog (2016) 97:148–53. doi:10.1016/j.micpath.2016.06.002
12. Maitra A, Kamal TK, Shaik M, Danquah CA, Chrzastek A, Bhakta S. Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): a report from Euroscicos international TB Summit 2016. Virulence (2016) 8(S):1005–24. doi:10.1016/j.viru.2016.12.0536
13. Catanzaro A, Rodwell TC, Catanzaro DG, Garfin RS, Jackson RL, Seifert M, et al. Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS One (2015) 10:1–14. doi:10.1371/journal.pone.0136861
14. Danquah CA, Maitra A, Gibbons S, Faill J, Bhakta S. HT-SPOTi: a rapid drug susceptibility test (DST) to evaluate antibiotic resistance profiles and novel anti-mycobiotic agents. Front Microbiol (2016) 7:401–12. doi:10.3389/fmicb.2016.00410
15. Dheda K, Barry CE, Maartens G. Tuberculosis. Lancet (2016) 387(10024):1211–26. doi:10.1016/S0140-6736(15)00151-8
16. Hancock REW, Haney EF, Gill EE. The immunology of host defence peptides and proteins in mycobacterial therapy: current status and future prospects. Tuberculosis (Edinb) (2014) 94:563–73. doi:10.1016/j.tube.2014.03.011
17. Mahlupu A, Häkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol (2016) 6:194. doi:10.3389/fcimb.2016.00194
18. Kosikowa P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat (2016) 26:689–702. doi:10.1586/13546105.2016.1176149
19. Diamond G, Beckloff N, Weinberg A, Kisch KO. The roles of antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects. Microbiology (2016) 162:964–73. doi:10.1099/mic.0.002829-t
20. Mishra AK, Driessen NN, Appelbeck BJ, Besra GS. Lipooarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol Rev (2011) 35:1126–57. doi:10.1016/j.femsre.2011.02.007
21. Abedinzadeh M, Geetin M, Sardari S. Natural antimicrobial peptides against Mycobacterium tuberculosis. Immunotherapy (2013) 5:1117–26. doi:10.3825/immther.2013.1111
22. Wharram S, Shi L, Chatterjee D, Belisle JT, Crick DC, McNeil MR. A bioanalytical method to determine the cell wall composition of Mycobacterium tuberculosis grown in vivo. Anal Biochem (2012) 421:240–9. doi:10.1016/j.abs.2011.10.046
23. NiyoTada F, Kiatsurayanon C, Chieosilapatham P, Ogawa H. Friends or foes? Host defense (antimicrobial) peptides and proteins in human skin diseases. Exp Dermatol (2017) 26(11):989–98. doi:10.1111/exd.13314
24. Banerjee DI, Gohil TP. Interaction of antimicrobial peptide with mycolyl transferase in Mycobacterium tuberculosis. Int J Mycobacteriol (2016) 5:83–8. doi:10.1016/j.jmyc.2015.07.002
25. Winkley WC. Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol (2010) 5:905–17. doi:10.1021/cb1001558

Frontiers in Immunology | www.frontiersin.org 12 November 2017 | Volume 8 | Article 1499

Host Antimicrobial Peptides against TB
42. Torrent M, Andreu D, Nogués VM, Boix E. Connecting peptide phyicochemical and antimicrobial properties by a rational prediction model. PLoS One (2011) 6:1. doi:10.1371/journal.pone.0016968.

43. Méndez-Samperio P. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections. Peptides (2010) 31:1791–8. doi:10.1016/j.peptides.2010.06.016.

44. Silva T, Magalhães B, Maia S, Gomes P, Nazmi K, Bolscher JGM, et al. Killing of Mycobacterium avium by lactoferricin peptides: improved activity of arginine- and d-amino-acid-containing molecules. Antimicrob Agents Chemother (2014) 58:3461–7. doi:10.1128/AAC.02728-13.

45. Rao M, Streur TL, Aldwell FE, Cook GM. Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG. Microbiology (2001) 147:1017–24. doi:10.1099/00221287-147-4-1017.

46. Santos P, Gordillo A, Oses L, Salazar LM, Soto CY. Effect of antimicrobial peptides on ATPase activity and proton pumping in plasma membrane vesicles obtained from mycobacteria. Peptides (2012) 36:121–8. doi:10.1016/j.peptides.2012.04.018.

47. Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol (2016) 24:862–71. doi:10.1016/j.tim.2016.06.009.

48. Le C-F, Fang C-M, Sekaran SD. Beyond membrane-lytic: intracellular targeting mechanisms by antimicrobial peptides. Antimicrob Agents Chemother (2017) 61:e02340–16. doi:10.1128/AAC.02340-16.

49. Sharma S, Verma I, Khuller KG. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv in vitro and in vivo study. Eur Respir J (2000) 16:112–7. doi:10.1034/j.1399-3003.2000.16a20.x.

50. Sharma S, Verma I, Khuller KG. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother (2001) 45:639–40. doi:10.1128/AAC.45.2.639-640.2001.

51. Sharma A, Pohane AA, Bansal S, Bajaj A, Jain V, Srivastava A. Cell penetrating synthetic antimicrobial peptides (SAMPs) exhibiting potent and selective killing of Mycobacterium by targeting its DNA. Chem (2015) 21:3540–5. doi:10.1002/chem.201404650.

52. Goldberg MF, Saini NK, Porcelli SA. Evasion of innate and adaptive immunity by Mycobacterium tuberculosis. Microbiol Spectr (2014) 2:1–24. doi:10.1128/microbiolspec.MGM2-0005-2013.

53. Soldati T, Neyrolles O. Mycobacteria and the intraphagosomal environment: take it with a pinch of salt(s)! Traffic (2012) 13:1042–52. doi:10.1111/j.1600-8542.2012.01358.x.

54. Verge I, Fratti RA, Hill PH, Chua J, Belsie J, Deretic V. Mycobacterium tuberculosis phagosomal maturation arrest: mycobacterial phosphatidylglycerol analog phosphatidylinositol mannoside stimulates early endosomal fusion. Mol Biol Cell (2004) 15:751–60. doi:10.1091/mbc.E03-05-0307.

55. Gemma M, Brumell JH. Interactions of pathogenic bacteria with autophagy systems. Curr Biol (2012) 22:R540–5. doi:10.1016/j.cub.2012.06.001.

56. Muciño G, Castro-Obregón S, Hernandez-Pando R, Del Rio G. Autophagy during infection and implications for future tuberculosis medications. Curr Host Microbe (2015) 3:719–96.

57. Kai-Larsen Y, Tholstrupdtto R, Guzman AM, Gudmundsson GH, Valdimarsson H, Johnston A. The anti-microbial peptide LL-37 modulates immune responses in the palate tonsils where it is exclusively expressed by neutrophils and a subset of dendritic cells. Clin Immunol (2012) 142:139–49. doi:10.1016/j.clim.2011.09.013.

58. Bøe AS, Morziane S, Trowbridge J, Schauer J, Kotod P, Bui JD, et al. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol (2009) 184:369–78. doi:10.4049/jimmunol.0902110.

59. Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol (2005) 7:179–96.

60. Kar-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense. Front Biosci (2008) 13:3760–70. doi:10.2741/2964.

61. Gupta S, Wingle K, Gallo RL. Bacterial subversion of cAMP signal ling inhibits cathelicidin expression, which is required for innate resistance to Mycobacterium tuberculosis. J Pathol (2017) 242:52–61. doi:10.1002/path.4878.

62. Campbell GR, Spector SA. Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1. J Immunol (2015) 195:8123–5. doi:10.4161/auto.121154.

63. Yuk J-M, Shin D-M, Lee H-M, Yang C-S, Jin HS, Kim K-K, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe (2009) 6:231–43. doi:10.1016/j.chom.2008.08.004.

64. Rekha RS, Rao Muva SV, Wan M, Raqbi R, Bergman P, Brighenti S, et al. Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages. Autophagy (2015) 11:1688–99. doi:10.1080/15548627.2015.1075110.

65. Bradfute SB, Castillo EE, Arko-Mensah J, Chauhan S, Jiang S, Mandell M, et al. Autophagy as an immune effector against tuberculosis. Curr Opin Microbiol (2013) 16:355–65. doi:10.1016/j.mib.2013.05.003.

66. Driss V, Legrand F, Herrmann E, Loeuse S, Goerardel Y, Kramer L, et al. TLR2-dependent eosiophil interactions with mycobacteria: role of α-defensins. Blood (2009) 113:3235–44. doi:10.1182/blood-2008-07-166595.

67. Duits LA, Ravensbergen R, Rademaker M, Hiemstra PS, Nibbering PH. Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology (2002) 106:517–25. doi:10.1046/j.1365-2567.2002.01430.x.

68. Rivas-Santiago B, Schwander SK, Sarabia C, Diamond G, Klein-Patel ME, Hernandez-Pando R, et al. Human [beta]-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun (2003) 71:4505–11. doi:10.1128/IAI.71.8.4505-4511.2005.

69. Dong H, Lv Y, Zhao D, Barrow P, Zhou X. Defensins: the case for their use against mycobacterial infections. J Immunol Res (2016) 2016:751687. doi:10.1155/2016/751687.
Prodefensins are matrix proteins of specific granules in human neutrophils. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, Faurschou M, Kamp S, Cowland JB, Udby L, Johnsen AH, Calafat J, et al. Ganz T. Defensins: antimicrobial peptides of innate immunity. Mycobacterium tuberculosis to restrict growth of human antimicrobial activity against cytosolic protein from human polymorphonuclear leukocytes, inhibits the growth of Bovrella burgdorferi. Infect Immun (2003) 71:4711–6. doi:10.1128/IAI.71.8.4711-4716.2003

Pires D, Marques J, Pombo JP, Carmo N, Bettencourt P, Neyrolles O, et al. Role of cathepsins in Mycobacterium tuberculosis survival in human macrophages. Sci Rep (2016) 6:32247. doi:10.1038/srep32247

Meijer AH. Protection and pathology in TB learning from the zebrafish model. Semin Immunopathol (2016) 38:261–73. doi:10.1007/s00281-015-0522-4

Pitabut N, Sakurada S, Tanaka T, Ridruecha C, Tanuma J, Aoki T, et al. Potential function of granulysin, other related effector molecules and lymphocyte subsets in patients with TB and HIV/TB coinfection. Int J Med Sci (2013) 10:1003–14. doi:10.7150/ijms.6437

Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med (1998) 4:615–8. doi:10.1038/nm599-615

Koczera P, Martin L, Marx G, Schuerholz T. The ribonuclease a superfamily in humans: canonical RNases as the buttress of innate immunity. J Immunol (2011) 242:161–77. doi:10.1111/j.1600-065X.2011.01026.x

Vijayan VK, Reetha AM, Jawahar MS, Sankaran K, Prabhakar R. Pulmonary eosinophilia in IgE-mediated processes. Respir Res (2011) 12:10. doi:10.1186/1465-9921-12-10

Monteseirín J, Vega A, Chacón P, Camacho MJ, El Bekay R, Asturias JA, et al. Neutrophils as a novel source of eosinophil cationic protein – a clue to the function of the eosinophil granulocyte. Clin Dev Immunol (2011) 2011:347594. doi:10.1155/2011/347594

Michels K, Nemeth E, Ganz T, Mehrad B. Hepcidin and host defense against bacterial resistance to antimicrobial peptides. Drug Resist Updat (2007) 10:6031–6. doi:10.1016/j.drup.2006.04.002

Liu Y-S, Tsai P-W, Wang Y, Fan T, Hsieh C-H, Chang M, et al. Chemoattraction of macrophages by secretory molecules derived from cells expressing the tumor necrosis factor alpha. Respir Res (2013) 14:175. doi:10.1186/1465-9921-14-175

Liao A, Yu J, Yen L, Wang S, Xu D, Zheng W, et al. The ribonuclease a superfamily in humans: canonical RNases as the buttress of innate immunity. J Mol Biol (2007) 370:785–93. doi:10.1016/j.jmb.20061104688

Tjandra I, Yu S, Tsi P-W, Wang Y, Fan T, Hsieh C-H, Chang M, et al. Chemotraction of macrophages by secretory molecules derived from cells expressing the signal peptide of eosinophil cationic protein. BMC Syst Biol (2012) 6:105. doi:10.1186/1752-0509-6-105

Lopes MF, Nunes MP, et al. Neutrophils activate macrophages for intracellular killing of Leishmania major through recruitment of TLR4 by neutrophil elastase. J Immunol (2007) 179:3989–94. doi:10.4049/jimmunol.179.6.3988

Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med (1998) 4:615–8. doi:10.1038/nm599-615

Pires D, Marques J, Pombo JP, Carmo N, Bettencourt P, Neyrolles O, et al. Role of cathepsins in Mycobacterium tuberculosis survival in human macrophages. Sci Rep (2016) 6:32247. doi:10.1038/srep32247

Meijer AH. Protection and pathology in TB learning from the zebrafish model. Semin Immunopathol (2016) 38:261–73. doi:10.1007/s00281-015-0522-4

Pitabut N, Sakurada S, Tanaka T, Ridruecha C, Tanuma J, Aoki T, et al. Potential function of granulysin, other related effector molecules and lymphocyte subsets in patients with TB and HIV/TB coinfection. Int J Med Sci (2013) 10:1003–14. doi:10.7150/ijms.6437

Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection. Int J Mol Med (2007) 118:3491–502. doi:10.3892/ijm.2012.6437

Foss MH, Powers KM, Purdy GE. Structural and functional characterization of mycobacterial ubiquitin-derived peptides in model and bacterial membranes. Biochemistry (2012) 51:9992–9. doi:10.1021/bi301426j

Koczera P, Martin L, Marx G, Schuerholz T. The ribonuclease a superfamily in humans: canonical RNases as the buttress of innate immunity. Int J Mol Sci (2017) 18:1278. doi:10.3390/ijms17081278

Bystrom J, Amin K, Bishop-Bailey D. Analysing the eosinophil cationic protein – a clue to the function of the eosinophil granulocyte. Respir Res (2011) 12:10. doi:10.1186/1465-9921-12-10

Monteseirín J, Vega A, Chacón P, Camacho MJ, El Bekay R, Asturias JA, et al. Neutrophils as a novel source of eosinophil cationic protein in IgE-mediated processes. Infect Immun (2007) 75:2634–41. doi:10.1128/immunol.179.4.2634

Liu Y-S, Tsai P-W, Wang Y, Fan T, Hsieh C-H, Chang M, et al. Chemotraction of macrophages by secretory molecules derived from cells expressing the signal peptide of eosinophil cationic protein. BMC Syst Biol (2012) 6:105. doi:10.1186/1752-0509-6-105

Vijayan VK, Reetha AM, Jawahar MS, Sankaran K, Prabhakar R. Pulmonary eosinophilia in pulmonary tuberculosis. Chest (1992) 101:1708–9. doi:10.1378/chest.101.6.1708

Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev (2011) 242:161–77. doi:10.1111/j.1600-065X.2011.01263.x

Arranz-Trullén J, Lu L, Pulido D, Bhakta S, Boix E. Unveiling the mode of action of human antimicrobial RNases against Mycobacterium tuberculosis.
using a surrogate macrophage infected model. *TB Summit 2016.* London (2016).

166. Gingras SK, Haigh BJ, Griffin FJ, Wheeler TT. The mammalian secreted Rbases: mechanisms of action in host defence. *Innate Immun* (2012) 19:86–97. doi:10.1080/17715349.2012.449655

167. Yang D, Chen Q, Su SB, Zhang J, Kurosaka K, Caspi RR, et al. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. *J Exp Med* (2008) 205:79–90. doi:10.1084/jem.20062027

168. Jiang Z, Higgins MP, Whitehurst J, Kisich KO, Voskuil MI, Hodges RS. Anti-tuberculosis activity of α-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37. *Protein Pept Lett* (2011) 18:241–52. doi:10.2174/092996671194578288

169. Kapoor R, Eimerman PR, Hardy JW, Cirillo JD, Contag CH, Barron AE. Efficacy of antimicrobial peptides against *Mycobacterium tuberculosis.* *Antimicrob Agents Chemother* (2011) 55:3058–62. doi:10.1128/AAC.01667-10

170. Hoffmann and Cazhal. Antibiotic peptides Patent WO2009013262 A1 (2009).

171. Ramón-García S, Mikut R, Ng C, Ruz, S. Volkmer R, Reischl M, et al. Targeting *Mycobacterium tuberculosis* and other microbial pathogens using improved synthetic antibacterial peptides. *Antimicrob Agents Chemother* (2013) 57:2295–303. doi:10.1128/AAC.00175-13

172. Rivas-Santiago B, Rivas Santiago CE, Castañeda-Delgado JE, León-Contreras JC, Hancock REW, Hernandez-Pando R. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CEP26 against *Mycobacterium tuberculosis.* *Int J Antimicrob Agents* (2013) 41:143–4. doi:10.1016/j.ijantimicag.2012.09.015

173. Lan Y, Lam JT, Siu GKH, Yam WC, Mason AJ, Lam JKW. Cationic amphipathic D-enantiomer antimicrobial peptides with in vitro and ex vivo activity against drug-resistant *Mycobacterium tuberculosis.* *Tuberculosis* (2014) 94:678–89. doi:10.1016/j.tube.2014.08.001

174. Kwok PCL, Grabarek A, Chow MYT, Lan Y, Li JCW, Cassetari L, et al. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. *Int J Pharm* (2015) 491:367–74. doi:10.1016/j.ijpharm.2015.07.001

175. Spindler EC, Hale JF, Giddings TH, Hancock REW, Gill RT. Decapering the mode of action of the synthetic antimicrobial peptide bac8c. *Antimicrob Agents Chemother* (2011) 55:1706–16. doi:10.1128/AAC.01053-10

176. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. *Cell* (1997) 88:553–60. doi:10.1016/S0092-8674(00)81195-4

177. Zhang J, Zhang X, Liu G, Chang D, Liang X, Zhu X, et al. Intracellular trafficking network of protein nanocapsules: endocytosis, exocytosis and autophagy. *Tobaccoology* (2016) 6:2099–12. doi:10.1016/j.tobacco.2016.02.011

178. Hamley I. Peptide fibrilization. *Angew Chem Int Ed Eng* (2007) 46:8128–47. doi:10.1002/anie.200700861

179. Torrent M, Valle J, Nogués MV, Boix E, Andrea D. The generation of antimicrobial peptide activity: a trade-off between charge and aggregation? *Angew Chem Int Ed Eng* (2011) 50:10686–9. doi:10.1002/anie.201103589

180. Mikkat R, Rudesen S, Reischl M, Breitling F, Volkmer R, Hilpert K. Improving short antimicrobial peptides despite elusive rules for activity. *Biochim Biophys Acta* (2016) 1858:1024–33. doi:10.1016/j.bbagen.2015.12.013

181. Haney EF, Mansour SC, Hilchey AL, de la Fuente-Núñez C, Hancock RE. High throughput screening methods for assessing antibiofilm and immunomodulatory activities of synthetic peptides. *Tuberculosis* (2015) 71:276–85. doi:10.1016/j.tube.2015.03.015

182. Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MUI1140. *J Pharm Sci* (2010) 99:2521–8. doi:10.1002/jps.20205

183. Rodriguez A, Villegas E, Montoya-Rosales A, Rivas-Santiago B, Corzo G. Characterization of antibacterial and hemolytic activity of synthetic pandinid 2 variants and their inhibition against *Mycobacterium tuberculosis.* *PLoS One* (2014) 9:e101742. doi:10.1371/journal.pone.0101742

184. Charka JS, Wang Y, Ke X-Y, Liu S, Newton SM, Langford PR, et al. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin. *Biomaterials* (2014) 35:2032–8. doi:10.1016/j.biomaterials.2013.11.035

185. Vermeer LS, Lan Y, Abbate V, Ruh E, Bui TT, Wilkinson LJ, et al. Comformational flexibility determines selectivity and antibacterial, antiplasmodial, and anticanccer potency of cationic α-helical peptides. *J Biol Chem* (2012) 287:34120–33. doi:10.1074/jbc.M111.359067

186. Rivas-Santiago B, Rivas Santiago CE, Sada E, Hernandez-Pando R. Prophylactic potential of defensins and L-isoleucine in tuberculosis household contacts.
an experimental model. *Immunotherapy* (2015) 7:207–13. doi:10.2217/imt.14.119

207. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* (2006) 311:1770–3. doi:10.1126/science.1123933

208. Lofton H, Pränting M, Thulin E, Andersson DI. Mechanisms and fitness costs of resistance to antimicrobial peptides LL-37, CNY100HL and wheat germ histones. *PLoS One* (2013) 8:e68875. doi:10.1371/journal.pone.0068875

209. Kraus D, Peschel A. Molecular mechanisms of bacterial resistance to antimicrobial peptides. *Curr Top Microbiol Immunol* (2006) 306:231–50.

210. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. *Cell* (2011) 145:39–53. doi:10.1016/j.cell.2011.02.022

211. Szumowski JD, Adams KN, Edelstein PH, Ramakrishnan L. Antimicrobial efflux pumps and *Mycobacterium tuberculosis* drug tolerance: evolutionary considerations. *Curr Top Microbiol Immunol* (2013) 374:81–108. doi:10.1007/82_2012_300

212. Rios AC, Moutinho CG, Pinto FC, Del Fiol FS, Jozala A, Chaud MV, et al. Alternatives to overcoming bacterial resistances: state-of-the-art. *Microbiol Res* (2016) 191:51–80. doi:10.1016/j.mires.2016.04.008

213. Gao LY, Laval F, Lawson EH, Groger RK, Woodruff A, Morisaki JH, et al. Requirement for kasB in *Mycobacterium mycolic* acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. *Mol Microbiol* (2003) 49:1547–63. doi:10.1046/j.1365-2958.2003.03667.x

214. Gryllos I, Tran-Winkler HJ, Cheng M-F, Chung H, Bolcombe R, Lu W, et al. Induction of group A *Streptococcus* virulence by a human antimicrobial peptide. *Proc Natl Acad Sci U S A* (2008) 105:16755–60. doi:10.1073/pnas.0803815105

215. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. *Nature* (2016) 529:336–43. doi:10.1038/nature17042

216. Bauer ME, Shafer WM. On the in vivo significance of bacterial resistance to antimicrobial peptides. *Biochim Biophys Acta* (2015) 1848:3101–11. doi:10.1016/j.bbamem.2015.02.012

217. Fattorini L, Gennaro R, Zanetti M, Tan D, Brunori L, Giannoni F, et al. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against *Mycobacterium tuberculosis*. *Peptides* (2004) 25:1075–7. doi:10.1016/j.peptides.2004.04.003

218. Nylen F, Bergman P, Gudmundsson GH, Agerberth B. Assays for identifying inducers of the antimicrobial peptide LL-37. *Methods Mol Biol* (2017) 1548:271–81. doi:10.1007/978-1-4939-6737-7_19

219. Ramos-Espinosa O, Hernández-Bazán S, Francisco-Cruz A, Mata-Espinosa D, Barrios-Payán J, Marquina-Castillo B, et al. Gene therapy based on antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis. *Pathog Dis* (2016) 74:ftw075. doi:10.1093/femspd/ftw075

**Conflict of Interest Statement:** No potential conflicts of interest were disclosed.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2017 Arranz-Trullén, Lu, Pulido, Bhakta and Boix. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*